FOLH1 and prostate carcinoma: In [177Lu]Lu-PSMA-617 therapy for metastasized prostate cancer, both the external dose rate of patients and the risk of radioactive contamination for caregivers and relatives are mainly determined by the urinary excretion of [177Lu]Lu-PSMA-617.